We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App

ThermoGenesis Launches Comprehensive Suite of COVID-19 Products and Services to Better Detect, Track and Fight Novel Coronavirus

By LabMedica International staff writers
Posted on 03 Sep 2020
Print article
ThermoGenesis Holdings, Inc. (Rancho Cordova, CA, USA), along with its joint venture ImmuneCyte Life Sciences, Inc.’s (Irvine, CA, USA), has launched a comprehensive COVID-19 product line that will combine diagnostic, therapeutic and service offerings to better detect, track and fight the novel coronavirus.

The spread of COVID-19 has led to a significant unmet need for rapid disease diagnosis, systematic serological surveillance and improved therapeutics, to precede and complement the introduction of vaccines. In response, ThermoGenesis, along with its joint venture ImmuneCyte, is developing a comprehensive list of RT-PCR and antigen test products to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit, which has already been granted Emergency Use Authorization (EUA). The joint venture also plans to offer full CLIA certified lab testing services to its clients, making ThermoGenesis a one-stop shop for all testing needs. Additionally, the ImmuneCyte joint venture is actively developing a robust therapeutic pipeline to treat COVID-19.

"The comprehensive diagnostic and therapeutic product pipeline we envisage for COVID-19 will facilitate ThermoGenesis' ability to become a one-stop solution for our customers," said Chris Xu, Ph.D, Chairman and Chief Executive Officer of ThermoGenesis. "This multi-pronged approach, we believe, will be critical to reopening the economy, tracking the virus, and minimizing the loss of life as we continue to develop and expand our product solutions for COVID-19."

Related Links:
ThermoGenesis Holdings, Inc.
ImmuneCyte Life Sciences, Inc.

Print article



view channel
Image: An enzyme-linked immunosorbent assay for mannose-binding lectin found that this molecule is associated with coagulopathy in severe COVID-19 patients (Photo courtesy of Getty Images).

Mannose-Binding Lectin Associated with Coagulopathy in Severe COVID-19

The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as profound effects on society. COVID-19 patients have an increased risk of thromboembolic (TE) complications,... Read more

Industry News

view channel

2020 AACC Annual Scientific Meeting & Clinical Lab Expo to Be an All Virtual Event Due to Coronavirus Pandemic

The American Association for Clinical Chemistry (AACC Washington, DC, USA) has decided to hold the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo as a virtual event, rather than as a live... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.